FDA Extends Review Of Wyeth/Progenics Methylnaltrexone NDA Until April
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA has pushed back the action date on Wyeth and Progenics' NDA for the subcutaneous formulation of methylnaltrexone, a peripherally acting mu-opioid receptor antagonist, until April 30, the companies announced Jan. 10
You may also be interested in...
R&D IN BRIEF
Methylnaltrexone disappoints Wyeth; updates on cancer vaccines; More R&D news, in brief
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.